COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05246137

Not reported

Not reported

2022-02-18

Completed

nonRCT

Non-randomized

Single group assignment

Open label

multi-center

Prevention

inclusion criteria: male or female, ≥ 16 years old at day 0. willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures. have a recognized primary vaccination scheme recognized by the authorities with comirnaty, spikevax, vaxevria or janssen at least 91 days and preferably a maximum of 240 days before day 0. if having an underlying illnesses must be stable and well-controlled according to the investigator judgment. participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine. participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination. female participant of childbearing potential must have a negative pregnancy test on the on day 0 prior to vaccination. female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom). male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence). male participants must refrain from donating sperm for at least 28 days after day 0.

history of anaphylaxis to any prior vaccine. previous severe sars-cov-2 infections that required >24 hous of hospitalisation. participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0. pregnancy or breast-feeding at screening or day 0 or willingness/intention to become pregnant during the study. having a clinically significant acute illness or fever (temperature ≥38º c (100.4ºf)) at screening or within 48 hours prior to day 0. participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration. having any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer. having ongoing severe and non-stable psychiatric condition likely to affect participation in the study. having problematic or risk use of substances including alcohol that can compromise the study follow-up. having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections. having abnormal function of the immune system, except stable clinical conditions like controlled hiv. having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening. chronic or recurrent administration of systemic immunosuppressant medication. having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (day 0) or expects to receive them during the study. having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat covid-19 within 90 days before day 0. participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study. participant has donated ≥ 450ml of blood products within 12 weeks before screening. participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.

1

Hipra Scientific, S.L.U

16

100

Italy;Spain

Healthy volunteers

N/A

2646

Incidence of Adverse Events in laboratory parameters (Safety and tolerability);Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs);Incidence of Serious Adverse Events (Safety and tolerability) (SAE);Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).;Incidence of Treatment-Emergent Adverse Events (Safety and tolerability);Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)

None

Phase 3

[{"arm_notes": "", "treatment_id": 1828, "treatment_name": "Phh-1v", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]